High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers In all, 142 (95%) of 150 questionnaires were completed by 38 ...
SAN DIEGO, March 13, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor ...
SAN DIEGO (KGTV) -- As an active 45-year-old man who loves to surf and take adventures with his daughter, Bryce Olson was the last person his friends expected to get cancer. In 2014, a call while at ...
Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer ...
In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen ...
Qiagen N.V. has announced that it is commercializing the research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to ...
* Qiagen NV - Qiagen has acquired an exclusive worldwide license from Johns Hopkins University Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback